Ramipril Recall After Packaging Error Raises Medication Mix-Up Risk

MHRA said Crescent Pharma Limited is recalling one batch of Ramipril 5 mg Capsules as a precautionary measure after a potential manufacturing error may have led to Amlodipine 5 mg Tablets being packed inside a carton labeled as Ramipril 5 mg Capsules. The agency said the issue came to light after a pharmacy complaint following a patient report.

This is a strong example of how medication safety can be compromised without any classical adverse-reaction signal. A packaging error can create a direct risk of unintended therapy, delayed correct treatment, and preventable harm.

For pharmacovigilance and quality teams, the case reinforces the importance of treating product-quality and packaging problems as part of the wider safety ecosystem. Inference: the sharp boundary some organizations place between “quality issues” and “drug safety issues” can become very thin when the patient receives the wrong medicine.